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© American Society for Clinical Pathology metastasis. [7] [8] [9] The current limitation in management of these patients underscores the need for developing alternate targeted therapies against signaling pathways for better stratification of patients to improve response to therapy. In addition, several studies have shown that recurrent/metastatic breast tumors may differ from primary tumors and can show discordance in hormone receptors (ER and PR) and HER2 expression, as well as at a genomic level. [10] [11] [12] [13] [14] Therefore, comparing genomic alterations in cancer-related genes between primary and metastatic breast tumors may provide insights into mechanisms of tumor metastases and drug resistance that may help guide targeted therapeutics. Recent technical advancements in massively parallel or high-throughput next-generation sequencing (NGS) offer multigene mutational profiling that provides comprehensive genetic information on breast cancer molecular pathology, paving the path for newer and more effective therapeutic targets. 15 In this study, we analyzed the results of our clinical molecular testing by NGS, using the Ion Torrent Personal Genome Machine (IT-PGM; Life Technologies, Carlsbad, CA), which uses nanograms of DNA and a semiconductorbased sequencing technology to interrogate tumors from patients with breast cancer using the IT AmpliSeq cancer panel. We have previously validated the IT AmpliSeq panel on the IT-PGM and use this platform for mutational screening of cancer specimens in our Clinical Laboratory Improvement Amendments-certified molecular diagnostic laboratory 15 under a prospective molecular profiling protocol for patients with breast cancer in whom treatment with investigational agents is being considered.
Materials and Methods

Tumor Samples
Patients with breast cancer were accrued from the MD Anderson Cancer Center (MDACC) Nellie B. Connally Breast Center and from the Clinical Center for Targeted Therapy on a prospective genomic testing protocol, "Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program" (NCT01772771). The study was approved by our institutional review board. After informed consent, tumor samples (n = 415) from 354 patients with breast cancer were analyzed, including both primary and metastatic sites when available. Specimens included formalin-fixed, paraffin-embedded core needle biopsy and tumor resection specimens and were reviewed by breast surgical pathologists at the MDACC using similar criteria as outlined below. Histologic grading was done using the Nottingham grading system combining nuclear grade, tubule formation, and mitotic rate and assigning a combined score of 1 (low grade), 2 (intermediate grade), or 3 (high grade). Immunohistochemical (IHC) staining for ER (antibody clone 6F11; Novocastra, Buffalo Grove, IL) and PR (antibody clone PgR1294; DAKO, Carpinteria, CA) was scored as positive if 1% or more of tumor cell nuclei were immunoreactive and negative if less than 1% of tumor cell nuclei were immunoreactive. 16 IHC for HER2 was performed using antibody AB8 (NeoMarkers, Fremont, CA) and scored as follows: IHC 3+, based on circumferential membrane staining that is complete, intense; IHC 2+, based on circumferential membrane staining that is incomplete and/or weak/moderate and within more than 10% of the invasive tumor cells or complete and circumferential membrane staining that is intense and within 10% or less of the invasive tumor cells; IHC 1+, as defined by incomplete membrane staining that is faint/barely perceptible and within more than 10% of the invasive tumor cells; IHC 0, as defined by no staining observed or membrane staining that is incomplete and is faint/barely perceptible and within 10% or less of the invasive tumor cells. 17 Equivocal or indeterminate cases were evaluated by fluorescence in situ hybridization using the following criteria: single-probe mean HER2 copy number of 6.0 or more signals/cell; dual-probe HER2/ CEP17 ratio of 2.0 or more, with a mean HER2 copy number of 4.0 or more signals/cell; dual-probe HER2/CEP17 ratio of 2.0 or more, with a mean HER2 copy number of less than 4.0 signals/cell; and dual-probe HER2/CEP17 ratio of less than 2.0, with a mean HER2 copy number of 6.0 or more signals/cell. 17 All histologic diagnoses, grading, and IHC staining were evaluated by the breast pathology service at the MDACC. All slides were reviewed by a pathologist to estimate for tumor percentage and circle the tumor-rich area for macrodissection/microdissection. Samples ranged between 20% and 100% of tumor, and tumor enrichment was done by either gross manual macrodissection or manual microdissection by light microscopy. Only cases with tumor more than 20% following tumor enrichment were included in this study.
Mutation Testing
DNA was extracted using standard methods and was analyzed for mutations as previously described. 15, 18 The IT AmpliSeq cancer panel is a multiplex polymerase chain reaction-based library preparation method that interrogates 190 regions comprising 740 mutational hotspots in the coding sequence of 46 cancer-related genes. The platform performs DNA sequencing by synthesis and detects the release of hydrogen ions during the incorporation of nucleotides during strand synthesis. 19 The change in pH is detected by an ion-sensitive field effect transistor and converted into sequence information by a signal-processing software. A mutant allele frequency of 10% was required to call a mutation in the patient sample. Details of the methods and the regions analyzed for each of the 46 genes on the panel are available in Supplemental Materials (all supplemental materials can be found at http://bit.ly/Roy-ChowdhuriNov15).
Data Analysis
Clinical NGS data and clinicopathologic characteristics were obtained from institutional pathology and clinical databases. Associations between categorical variables (PIK3CA+ and PIK3CA-in ER/PR+HER2-and ER/PR/ HER2-patients; TP53+ and TP53-in ER/PR+HER2-and ER/PR/HER2-patients) were examined using contingency tables and the Fisher exact test. P values less than .05 were considered as significant.
Results
Tumor specimens (n = 415) from 354 patients with breast cancer were analyzed in this study, including primary (n = 305) and recurrent/metastatic tumors (n = 110). Of the 354 patients studied, 61 had mutational analysis performed on both the primary as well as metastatic sites. Histologic subtypes included ductal carcinoma (n = 274/354; 77.4%), lobular carcinoma (n = 29/354; 8.2%), mixed (ductal and lobular features) (n = 17/354; 4.8%), metaplastic carcinoma (n = 14/354; 4%), and carcinoma not otherwise specified (NOS) (n = 20/354; 5.6%). The 20 patients who were categorized as having carcinoma NOS were patients with metastatic carcinoma who did not have their prior pathology of the primary tumor available for review and were not further subtyped. The median age of the patients analyzed was 46 years (range, 23-75 years). The clinicopathologic features of the patients, including age, sex, ethnicity, stage at diagnosis, histologic subtype, and ER/PR/HER2 status, are summarized in ❚Table 1❚.
A total of 220 (62.1%) of 354 patients were identified with somatic nonsynonymous mutations in known hotspots of 26 of the 46 common cancer-related genes tested. A subset of patients (n = 47; 13.3%) had two or more mutations present in their tumor, resulting in an overall detection of 281 somatic nonsynonymous mutations. Most mutations were missense mutations (n = 242; 86%), with 25 nonsense mutations leading to truncation of the protein (TP53, n = 22; PTEN, n = 3) and 14 insertion/deletions (TP53, n = 12; PIK3CA, n = 1; ERBB2, n = 1) (data not shown).
Overall, TP53 was most frequently mutated (n = 109; 38.8%), followed by PIK3CA (n = 89; 31.7%), AKT1 (n = 17; 6%), ATM (n = 11; 3.9%), STK11 (n = 6; 2.1%), APC (n = 6; 2.1%), MET (n = 4; 1.4%), ABL1 (n = 4; 1.4%), PTEN (n = 4; 1.4%), SMAD4 (n = 3; 1%), BRAF (n = 3; 1%), EGFR (n = 3; 1%), HRAS (n = 3; 1%), and KRAS (n = 3; 1%) ❚Table 2❚. Mutations were detected at a lower frequency (<1%) in MLH1, RET, MPL, ERBB2, FGFR2, SRC, KDR, FGFR1, JAK3, NOTCH1, NRAS, and ERBB4 ( Table 2 ). The mutation frequencies seen in the 26 genes categorized by histologic subtype are summarized in Table 2 .
Mutations were also classified according to the histologic grade of tumor (when available; n = 300), and the results are shown in ❚Table 3❚. TP53 mutations were seen in 41% of all high-grade tumors (n = 75/181), with none detected in any low-grade tumors. Low-grade tumors showed predominantly PIK3CA mutations (n = 10/14; 71%). TP53 mutations were seen concomitantly with PIK3CA mutations (n = 18), with 12 patients from the ER/PR+HER2-group, one from the ER/PR+HER2+ group, one from the ER/PR-HER2+ group, and four from the triple-negative (ER/PR/ HER2-) group (data not shown).
The four clinically relevant therapeutic groups showed distinct mutational profiles. Of the 220 patients with somatic mutations and available ER/PR/HER2 status, mutations were detected in tumors of 60% of ER/PR+HER2-patients © American Society for Clinical Pathology (n = 132), 9% of ER/PR+HER2+ patients (n = 20), 1.8% of ER/PR-HER2+ patients (n = 4), and 29% of triple-negative (ER/PR/HER2-) patients (n = 64). The ER/PR+HER2-group demonstrated the most heterogeneous mutation spectrum, with somatic mutations detected in 21 of 46 genes tested ❚Figure 1❚. PIK3CA had the highest mutation frequency (n = 67/176; 38%), followed by TP53 (n = 48; 27%), AKT1 (n = 15; 9%), ATM (n = 8; 5%), ABL1 (n = 4; 2%), STK11 (n = 4; 2%), PTEN (n = 3; 2%), APC (n = 3; 2%), KRAS (n = 3; 2%), BRAF (n = 2; 1%), EGFR (n = 2; 1%), ERBB2 (n = 2; 1%), HRAS (n = 2; 1%), MPL (n = 2; 1%), MLH1 (n = 2; 1%), ERBB4 (n = 1; 1%), FGFR2 (n = 1; 1%), KDR (n = 1; 1%), NOTCH1 (n = 1; 1%), NRAS (n = 1; 1%), and SMAD4 (n = 1; 1%) ( Figure 1) . The number of patients in the HER2-positive group (ER/PR+HER2+ and ER/PR-HER2+) was relatively small (n = 24). The most common mutation detected among the 20 patients with ER/PR+HER2+ tumors was TP53 (n = 9; 41%), followed by PIK3CA (n = 8; 36%), AKT1 (n = 1; 5%), ABL1 (n = 1; 5%), ATM (n = 1; 5%), EGFR (n = 1; 5%), and STK11 (n = 1; 5%) ( Figure 1 ). The six ER/PR-HER2+ tumors showed predominantly TP53 mutations (n = 4; 67%), along with PIK3CA (n = 1; 17%) and ATM (n = 1; 17%) mutations (Figure 1 ). Although the sample size of the HER2-positive patients was small, which precluded statistical analysis, the ER/PR-patients in the group had a higher number of TP53 mutations compared with the ER/PR+ patients (67% vs 41%). The triple-negative group (ER/PR/HER2-) showed mutations in 15 of 46 genes tested with the highest mutation frequency seen in TP53 (n = 48/77; 62%), followed by PIK3CA (n = 13/77; 17%), APC (n = 2; 3%), RET (n = 2; 3%), SMAD4 (n = 2; 3%), AKT1 (n = 1; 1%), ATM (n = 1; 1%), BRAF (n = 1; 1%), FGFR1 (n = 1; 1%), HRAS (n = 1; 1%), JAK3 (n = 1; 1%), MET (n = 1; 1%), SRC (n = 1; 1%), PTEN (n = 1; 1%), and STK11 (n = 1; 1%) ( Figure 1) . The Fisher exact test was used to compare the frequency of the two most commonly mutated genes, TP53 and PIK3CA, between ER/PR+HER2-tumors and ER/PR/HER2-tumors ❚Table 4❚. PIK3CA mutations showed a positive correlation with ER/PR+HER2-tumors (P < .001), while TP53 mutations were positively correlated with ER/PR/HER2-tumors (P < .001) ( Table 4 ).
In addition, 61 patients had paired primary and metastatic tumors tested, of which 47 (77%) patients showed identical results in the primary tumor and the metastasis tested-that is, either no mutations detected in the primary/metastasis or had the same mutation detected in both the primary and metastasis tested ❚Table 5❚, ❚Table 6❚, and ❚Figure 2❚. Thirteen patients had additional mutations 
NOS, not otherwise specified. a Some patients had two or more mutations detected in the same tumor.
detected in the metastasis that were not present in the primary tumor, including mutations in TP53 (n = 5), PIK3CA (n = 4), KRAS (n = 2), PTEN (n = 1), BRAF (n = 2), and AKT1 (n = 1) ( Table 6 and Figure 2 ). The mutation allelic frequency for 12 of 13 metastatic tumors was in keeping with the estimated tumor content for each case (Table 6) , and none of the additional mutations were present in the primary tumors, suggesting that these mutations were newly acquired mutations in the metastatic tumor. Patient 7 had an additional BRAF mutation present at a low allelic frequency (approximately 9%), which was in discordance with the estimated tumor content (80%) as well as the allelic frequency of the concurrent mutations in TP53, PIK3CA, and APC ( Table 6 ).
The significance of such low-level mutations is unknown. An additional patient (patient 24) had a very low allelic frequency (approximately 5%) PTEN mutation detected in the primary tumor that was not seen in the metastasis tested (Table 6 ). Although the significance of this is unclear, it may represent a low-level subclonal population that was present in the primary tumor but not detected/present in the subsequent metastasis. 
Discussion
Treatment of breast cancer currently depends on the expression of receptors for estrogen, progesterone, and HER2, and only tumors with high expression of these receptors respond well to hormone/endocrine therapy or anti-HER2 therapy. 20, 21 Triple-negative breast cancer, which accounts for approximately 15% to 20% of all breast cancers and consists of a heterogeneous collection of tumors defined by a lack of clearly defined biomarkers, is typically treated by chemotherapy alone. 9, [22] [23] [24] Mutational profiling of patients with breast cancer provides a novel mechanism of identification of genetic alterations using small amounts of DNA to characterize breast cancer subtypes at a molecular level to identify biomarkers for therapeutic targets. 1, 24 Our study focused on patients with primary and metastatic breast cancer, predominantly women aged 23 to 75 years (Table 1) . Our cohort showed a large number of patients (20%) with stage IV disease (national average is <5%), which may be due to referral bias of a large tertiary cancer center. The results show that a significant number of patients (62.1%) with breast cancer in our study harbor somatic nonsynonymous mutations in multiple cancerrelated genes detected by our hotspot NGS platform, with TP53 and PIK3CA being the most frequently mutated genes. These results are similar to previously published studies on molecular analysis of patients with breast cancer in whom TP53 and PIK3CA are the most commonly mutated genes detected. 1, 25 The overall mutation frequency seen in our study for most of the genes was similar to The Cancer Genome Atlas (TCGA) data for sequenced tumors. 1, 26, 27 The mutation frequency of AKT1 was higher in our study (6% vs 2%), while the frequency of PTEN mutations was lower (1.4% vs 4%) compared with the TCGA data set. 1, 26, 27 This may in part be attributable to the fact that the AmpliSeq panel detects only hotspot mutations; thus, we may be underestimating mutations in PTEN (as well as TP53), which may be along the entire length of the gene and not only at the 
© American Society for Clinical Pathology hotspots. In addition, our study identified rare mutations that were not seen in the TCGA data, including mutations in STK11, HRAS, NRAS, MPL, SRC, and FGFR1. Although overall our data are similar to the TCGA data set, there are minor differences that may be due to several reasons: (a) our patient cohort represents a large tertiary cancer center, and our study selectively recruited advanced-stage patients, while in contrast, the TCGA focused primarily on patient samples from operable breast cancer; (b) we are analyzing only hotspot regions vs whole-exome/genome analysis; and (c) tumor heterogeneity may account for differences in some of the mutations detected. When stratified into the four clinically relevant therapeutic groups (ER/PR+HER2-, ER/PR+HER2+, ER/PR-HER2+, ER/PR/HER2-), each group in our study showed distinct mutational profiles. The ER/PR+HER2-tumors showed a more heterogeneous mutational spectrum with mutations detected in 21 of 46 cancer-related genes tested (Figure 1) . The highest numbers of mutations were seen in PIK3CA (38%), TP53 (27%), AKT1 (9%), ATM (5%), ABL1 (2%), and APC (2%) (Figure 1 ), similar to molecular portraits reported in other studies. 1, 25 The HER2-positive tumors showed mutations in TP53, PIK3CA, ATM, EGFR, STK11, AKT1, and ABL1 with higher numbers of TP53 mutations (67%) in the ER/PR-HER2+ patients (vs 41% in ER/PR+HER2+). Although the sample size of this group was small (n = 24), precluding statistical analysis, these findings are in concordance with the TCGA studies. 1 In contrast, patients with triple-negative (ER/PR/HER2-) tumors had significantly higher mutation frequency of TP53 (62%) than PIK3CA (17%) (P < .001), which would suggest a loss of TP53 function commonly found in these tumors. It should also be noted that the TP53 mutation rates in this study may be an underestimation, since we performed 
known mutational hot spot testing rather than whole-exome sequencing of TP53. Mutational analyses of matched primary and metastatic tumors in our study showed an overall concordance in 77% of the patients tested. Approximately 22% of patients showed additional mutations in the metastatic tumor that were not detected in the primary tumor. The change in mutation profile was independent of the tumor biomarker status (ER/PR and/or HER2). Although these findings may provide insights into clonal evolution, mechanisms of metastases, and drug resistance, the small sample size (n = 61) limits the power of this study. Thirteen percent of patients in our study had potentially actionable mutations in the metastases that were not detected in the primary tumor, suggesting that whenever tissue is available for testing, mutational profiling should be performed on the metastatic tumor to identify mutations that can mediate sensitivity or resistance to specific targeted therapy.
Mutational analysis in patients with breast cancer has remained a fertile ground for biomarker research partly due to the clinical heterogeneity and varied outcome seen in patients. 21 Although several therapies exist for patients with metastatic breast cancer, there are a variety of mechanisms of intrinsic and acquired resistance to existing therapies. Metastatic breast cancer remains largely incurable, and thus there is a pressing need for novel treatment options. 21 Our results indicate that breast cancers show a heterogeneous mutation spectrum and can harbor mutations that may be © American Society for Clinical Pathology potentially targetable. Almost half the mutations (n = 139; 49%) detected in our study can be potentially targeted, directly or indirectly, with therapeutic agents that are currently in preclinical and clinical trials, including targets such as HER2, PIK3CA, PTEN, AKT1, BRAF, EGFR, RAS, RET, MET, and FGFR1/2. Detailed level of evidence for some of these targets is available on our Personalized Cancer Therapy website (www.personalizedcancertherapy.org). However, most of these mutations have not been shown to predict response to therapy yet, and genes that are "actionable" continue to be a moving target as we learn more about molecular pathways and design therapies against different molecules in signaling pathways.
Molecular analyses of clinical subgroups of breast cancer extend our knowledge of molecular subtyping based on likely driver mutations, which may open up doors for potential novel therapeutics. NGS allows massively parallel sequencing of multiple genes in multiple samples simultaneously and can identify markers that can have direct implications on patient management. In conclusion, NGS studies are forging new therapeutic road maps based on molecular subtyping and genomically informed therapy.
❚Figure 2❚ Mutation analyses of matched primary and metastatic tumors in breast cancer (n = 61). Matched primary (P) and metastasis (M) from 61 patients with breast cancer showing patients with no mutation (nm) in either primary or metastasis (n = 24) and patients who had mutations detected in the primary and/or metastasis (n = 47). Mutations detected/no mutations in the primary sample are designated in green; mutations detected/no mutations in the metastasis when concordant with the primary are designated in yellow; additional mutations (P/M) detected are designated in red (n = 14). nm  nm  TP53  TP53  PIK3CA  PIK3CA  KRAS  KRAS  BRAF  BRAF  HRAS  HRAS  PTEN  PTEN  STK11  STK11  MPL  MPL  MET  MET  ATM  ATM  APC  APC  AKT1  AKT1 ABL1 ABL1
